Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24180058 | 0.84 | MAP3K14 (0.35) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL13007383 | 0.77 | MAP3K14 (0.38) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL9247739 | 0.77 | POLB (0.40) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL10029440 | 0.77 | MAP3K14 (0.38) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL6598019 | 0.74 | NPC1 (0.42) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL18888757 | 0.72 | NPC1 (0.41) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL15606251 | 0.72 | MAP3K14 (0.40) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL17651927 | 0.71 | MAP3K14 (0.36) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL10794652 | 0.71 | ALDH1A1 (0.42) | DDB1CRBNMAP3K14SMN1; SMN2 | |
| SCHEMBL24756756 | 0.71 | ALDH1A1 (0.42) | DDB1CRBNMAP3K14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20210379195-A1 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | REGENERON PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379195-A1 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | CD81, CD2, CD44 | DDB1 3538/4885CRBN 603/4885MAP3K14 3271/4885 |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | CD44, LY6K, CD2 | DDB1 1225/4885CRBN 1940/4885MAP3K14 3506/4885 |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | DDB1 3252/4885CRBN 300/4885MAP3K14 4108/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | DDB1 2414/4885CRBN 583/4885MAP3K14 4024/4885 |
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD59, CD58, CD2 | DDB1 2187/4885CRBN 1156/4885MAP3K14 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.